Información de Celldex Therapeutics Inc, dividendo de Celldex Therapeutics Inc, actividades de los accionistas y más

Más Datos de Celldex Therapeutics Inc Compañía

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Información de Celldex Therapeutics Inc



Símbolo de cotizaciónCLDX

Nombre de la empresaCelldex Therapeutics Inc

Fecha de salida a bolsaMay 15, 1986

Director ejecutivoMr. Anthony S. Marucci

Número de empleados186

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 15

Dirección53 Frontage Road

CiudadHAMPTON

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal08827

Teléfono19084547120

Sitio Webhttps://celldex.com/

Símbolo de cotizaciónCLDX

Fecha de salida a bolsaMay 15, 1986

Director ejecutivoMr. Anthony S. Marucci

Ejecutivos de Celldex Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Mr. Herbert J. (Herb) Conrad

Independent Director

2.56K

--

Mr. James J. (Jim) Marino

Independent Director

2.20K

--

Mr. Keith L. Brownlie, CPA

Independent Director

666.00

--

Ms. Teri L. Lawver

Senior Vice President, Chief Commercial Officer

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Otro

60.89%

Accionistas

Proporción

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Otro

60.89%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

42.58%

Hedge Fund

32.92%

Investment Advisor/Hedge Fund

31.28%

Venture Capital

3.61%

Research Firm

2.78%

Pension Fund

0.39%

Bank and Trust

0.36%

Individual Investor

0.27%

Insurance Company

0.04%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

420

73.66M

110.92%

-14.44M

2025Q2

422

75.86M

114.26%

-13.90M

2025Q1

437

75.31M

113.46%

-13.68M

2024Q4

437

75.05M

113.05%

-8.14M

2024Q3

429

73.28M

110.59%

-7.16M

2024Q2

432

71.48M

107.86%

-10.62M

2024Q1

419

71.32M

108.50%

+952.72K

2023Q4

406

62.72M

112.33%

-412.93K

2023Q3

403

52.10M

110.18%

-8.63M

2023Q2

410

51.84M

109.57%

-7.47M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Wellington Management Company, LLP

5.23M

7.88%

-3.12M

-37.37%

Jun 30, 2025

Kynam Capital Management LP

6.10M

9.19%

-399.27K

-6.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.59M

6.91%

-38.52K

-0.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.95M

5.95%

+62.97K

+1.62%

Jun 30, 2025

The Vanguard Group, Inc.

3.94M

5.94%

+56.45K

+1.45%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.75M

5.65%

+398.14K

+11.88%

Jun 30, 2025

Commodore Capital LP

3.45M

5.2%

+100.00K

+2.99%

Jun 30, 2025

Bellevue Asset Management AG

3.31M

4.98%

+235.95K

+7.68%

Jun 30, 2025

Point72 Asset Management, L.P.

2.80M

4.22%

+180.55K

+6.89%

Jun 30, 2025

State Street Investment Management (US)

2.41M

3.62%

-400.86K

-14.28%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Simplify Propel Opportunities ETF

3.32%

ALPS Medical Breakthroughs ETF

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.92%

SPDR S&P Biotech ETF

0.65%

Direxion Daily S&P Biotech Bull 3X Shares

0.34%

Avantis US Small Cap Equity ETF

0.15%

First Trust Small Cap Growth AlphaDEX Fund

0.14%

Nuveen ESG Small-Cap ETF

0.14%

Fidelity Fundamental Small-Mid Cap ETF

0.13%

T Rowe Price Small-Mid Cap ETF

0.12%

Simplify Propel Opportunities ETF

Proporción3.32%

ALPS Medical Breakthroughs ETF

Proporción1.02%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.92%

SPDR S&P Biotech ETF

Proporción0.65%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.34%

Avantis US Small Cap Equity ETF

Proporción0.15%

First Trust Small Cap Growth AlphaDEX Fund

Proporción0.14%

Nuveen ESG Small-Cap ETF

Proporción0.14%

Fidelity Fundamental Small-Mid Cap ETF

Proporción0.13%

T Rowe Price Small-Mid Cap ETF

Proporción0.12%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos